EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Glucocorticoid Receptor Signaling in NSCLC: Mechanistic Aspects and Therapeutic Perspectives

Kostas A Papavassiliou iD, Nektarios Anagnostopoulos iD, Athanasios G Papavassiliou iD

Biomolecules · 2023

DOI: 10.3390/biom13091286 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Kostas A Papavassiliou und 2 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Respiratory Medicine, 'Sotiria' Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Receptors, Glucocorticoid. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent advances in non-small cell lung cancer (NSCLC) biology and the discovery of novel therapeutic targets have led to the development of new pharmacological agents that may improve the clinical outcome of patients with NSCLC. The glucocorticoid receptor (GR) is an evolutionarily conserved protein belonging to the nuclear receptor superfamily of transcription factors and mediates the diverse actions of glucocorticoids in cells. Data suggest that the GR may play a relevant role in the molecular mechanisms of NSCLC tumorigenesis and malignant progression. Additionally, evidence indicates that glucocorticoids may affect the efficacy of standard treatment, including chemotherapy, immune checkpoint inhibitors, and targeted therapy. Furthermore, several findings show that GR expression may probably be associated with NSCLC patient survival. Finally, glucocorticoids may be used as therapeutic agents for the clinical management of NSCLC patients. Here, we briefly review the latest advances on the biological role of GR signaling in NSCLC and discuss the potential use of the GR as a prognostic and predictive biomarker. Importantly, we explore the therapeutic potential of glucocorticoids and the effect of adding such drugs to standard therapies for NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsReceptors, GlucocorticoidHumansGlucocorticoidsSignal Transduction

Stichwörter der Autor:innen

glucocorticoid receptorglucocorticoidsnon-small cell lung cancer

Substanzen

GlucocorticoidsReceptors, Glucocorticoid

Autor:innen und Institutionen

  • First Department of Respiratory Medicine, 'Sotiria' Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.

ORCID-Profile: Kostas A Papavassiliou, Nektarios Anagnostopoulos, Athanasios G Papavassiliou

Zitieren

APA

Papavassiliou, K. A., Anagnostopoulos, N., & Papavassiliou, A. G. (2023). Glucocorticoid Receptor Signaling in NSCLC: Mechanistic Aspects and Therapeutic Perspectives. Biomolecules. https://doi.org/10.3390/biom13091286

Vancouver

Papavassiliou KA, Anagnostopoulos N, Papavassiliou AG. Glucocorticoid Receptor Signaling in NSCLC: Mechanistic Aspects and Therapeutic Perspectives. Biomolecules. 2023. doi:10.3390/biom13091286

BibTeX
@article{Papavassiliou2023,
  author = {Papavassiliou, Kostas A and Anagnostopoulos, Nektarios and Papavassiliou, Athanasios G},
  title = {Glucocorticoid Receptor Signaling in NSCLC: Mechanistic Aspects and Therapeutic Perspectives},
  journal = {Biomolecules},
  year = {2023},
  doi = {10.3390/biom13091286}
}
Kostenlos starten →